Nucleic Acid Amplification Testing Market, By Type, By Application, By End-use, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

REPORT HIGHLIGHT

The Nucleic Acid Amplification testing Market size was valued at US$9,897.45 Million in 2024, expanding at a CAGR of 9.5% from 2025 to 2032.
The Nucleic Acid Amplification Testing market is experiencing robust global growth driven by the rising prevalence of infectious diseases worldwide and continuous technological advancements in molecular diagnostics. NAAT, a highly sensitive technique, is the gold standard for detecting and quantifying nucleic acids (DNA or RNA) and is vital in diagnosing conditions such as COVID-19, HIV, and Tuberculosis. The growing demand for rapid, decentralized Point-of-Care (POC) testing and the increasing application of NAAT in oncology and personalized medicine are key factors propelling market expansion.

Nucleic Acid Amplification testing Market- Market Dynamics

Rising Prevalence of Infectious Diseases and Public Health Crises
The rising prevalence of infectious diseases, including respiratory infections, sexually transmitted infections (STIs), and newly emerging or re-emerging pathogens, presents significant challenges for global public health systems, driven by factors such as globalization, urbanization, and climate change, For instance, according to the World Health Organization (WHO), approximately 10.8 million people were reported to have fallen ill with Tuberculosis (TB) globally in 2023, encompassing 6.0 million men, 3.6 million women, and 1.3 million children . In response, the adoption of Nucleic Acid Amplification Tests (NAAT) has become essential, primarily due to its high sensitivity and specificity, which facilitate early detection of infections even before symptoms appear. This early identification enables timely treatment, effectively minimizing adverse health outcomes and transmission rates, especially in the case of STIs. Moreover, NAAT plays a crucial role in public health surveillance, allowing for rapid testing during outbreaks and thereby aiding in the control of disease spread. Its adaptability to detect new pathogens is vital for responding to public health emergencies, underscoring the need for integrating NAAT into routine health strategies to enhance preparedness and resource allocation in combating infectious diseases.

Nucleic Acid Amplification testing Market- Segmentation Analysis:

The Global Nucleic Acid Amplification testing Market is segmented on the basis of Type, Application, End-use, and Region.
Based on Type, the market is divided into Polymerase Chain Reaction (PCR) Tests, Isothermal Nucleic Acid Amplification Technology (INAAT) Tests, and Others. PCR tests hold the largest share due to their high sensitivity, versatility, and widespread use in diagnostic and research applications, while INAAT tests are gaining traction for their rapid processing and suitability for point-of-care testing.
Based on Application, the market is divided into Infectious Disease Testing, Oncology Testing, Genetic & Mitochondrial Disease Testing, and Other Applications. Infectious disease testing accounts for the largest market share due to the rising prevalence of viral and bacterial infections, increasing demand for accurate diagnostic solutions, and widespread adoption of molecular testing in clinical laboratories.
Based on end use the market is divided into Central and Reference Laboratories, Point-of-Care Settings, Biotechnology & Pharmaceutical Companies, and Academic & Research Institutes and others. Central and reference laboratories account for a significant share due to their extensive testing services and commitment to accuracy and reliability in diagnostics. Point-of-care settings are experiencing rapid growth as demand increases for immediate diagnostic solutions that facilitate prompt clinical decision-making, particularly in urgent and remote care environments.

Nucleic Acid Amplification testing Market- Geographical Insights

The Nucleic Acid Amplification Testing market is predominantly driven by North America, which holds the largest share due to advanced healthcare infrastructure, significant investment in research and development, and a high prevalence of infectious diseases. Following North America, the Asia Pacific region is experiencing substantial growth, propelled by rising healthcare expenditures, increasing demand for accurate diagnostic solutions, and a growing population with diverse health challenges. Europe ranks next, benefiting from robust healthcare systems and strong regulatory support for molecular diagnostics. Latin America (LATAM) is also witnessing growth, although at a slower pace, as improvements in healthcare access and rising awareness of infectious diseases contribute to the market's expansion. Lastly, the Middle East and Africa (MEA) region faces challenges such as limited healthcare resources, but efforts to enhance healthcare infrastructure and increasing disease awareness are gradually fostering market growth. Overall, the global distribution reflects varying levels of healthcare maturity and investment in diagnostic technologies.

Nucleic Acid Amplification testing Market- Country Insights

The United States is the dominant market for Nucleic Acid Amplification Testing (NAAT), driven by its advanced healthcare infrastructure, significant investment in research and development, and a high incidence of infectious diseases. The demand for accurate and rapid diagnostic solutions has fostered widespread adoption of NAAT across clinical laboratories, hospitals, and point-of-care settings. Additionally, the U.S. benefits from a strong regulatory framework that supports innovative diagnostic technologies. Other notable markets include Canada and Mexico, which are also experiencing growth due to increasing healthcare expenditures and rising awareness of molecular diagnostics, contributing to a robust North American market landscape.

Nucleic Acid Amplification testing Market- Competitive Landscape:

The Nucleic Acid Amplification Testing (NAAT) market is highly competitive, featuring key players like Roche, Abbott Laboratories, and Thermo Fisher Scientific, known for their innovative diagnostic solutions and extensive product portfolios. bioMérieux and Hologic focus on infectious disease testing, enhancing their market presence through advanced technologies and strategic partnerships. QIAGEN and Bio-Rad Laboratories emphasize assay development and molecular diagnostics, while Danaher leverages its strong R&D capabilities to drive growth. Grifols S.A. and Seegene Inc. are also making strides in the market, contributing unique technologies and expanding their geographical reach, thereby intensifying competition and fostering innovation in NAAT applications. These companies emphasize technological innovation, expansion of product portfolios, and strategic partnerships to enhance their global footprint. For instance, In July 2025, South Korea-based Seegene Inc. launched its CURECA fully automated PCR testing system alongside its STAgora data analytics platform. CURECA is notable as the world's first system to completely automate the entire PCR testing process, which includes everything from sample storage and pre-treatment to nucleic acid extraction, amplification, and final result analysis, requiring no human intervention. Seegene states that the introduction of these new technologies represents a transformative shift in the global diagnostics paradigm.

Recent Developments:

In September 2024 Takara Bio USA, Inc. introduced the SmartChip ND Real-Time PCR System, an automated, high-throughput quantitative PCR (qPCR) solution designated for research-use-only (RUO). This system is designed specifically for monitoring antimicrobial resistance (AMR), addressing the increasing global need for advanced tools in environmental safety and sustainability research.
In December 2025 Roche introduced the cobas BV/CV Assay, a new PCR-based diagnostic test that has received the CE Mark for use in accepting countries. This assay is designed to streamline the diagnostic workflow for vaginitis by utilizing a single vaginal swab to rapidly and accurately detect the bacteria responsible for bacterial vaginosis and the yeast associated with candida vaginitis.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Roche (F. Hoffmann-La Roche Ltd.)
Abbott Laboratories
Thermo Fisher Scientific Inc.
bioMérieux
Hologic
QIAGEN
Bio-Rad Laboratories
Danaher
Grifols S.A.
Seegene Inc.
Others

GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY TYPE - MARKET ANALYSIS, 2019 - 2032

Polymerase Chain Reaction (PCR) Tests
Isothermal Nucleic Acid Amplification Technology (INAAT) Tests
Others

GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY APPLICATION - MARKET ANALYSIS, 2019 - 2032

Infectious Disease Testing
Oncology Testing
Genetic & Mitochondrial Disease Testing
Others

GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY END-USE - MARKET ANALYSIS, 2019 - 2032

Central and Reference Laboratories
Point-of-Care Settings
Biotechnology & Pharmaceutical Companies
Academic & Research Institutes
Others

GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more